Aaron Weitzman

2.4k total citations · 1 hit paper
38 papers, 1.2k citations indexed

About

Aaron Weitzman is a scholar working on Oncology, Genetics and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Aaron Weitzman has authored 38 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 13 papers in Genetics and 13 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Aaron Weitzman's work include Chronic Lymphocytic Leukemia Research (12 papers), Chronic Myeloid Leukemia Treatments (12 papers) and Eosinophilic Disorders and Syndromes (10 papers). Aaron Weitzman is often cited by papers focused on Chronic Lymphocytic Leukemia Research (12 papers), Chronic Myeloid Leukemia Treatments (12 papers) and Eosinophilic Disorders and Syndromes (10 papers). Aaron Weitzman collaborates with scholars based in United States, Germany and United Kingdom. Aaron Weitzman's co-authors include Francis J. Giles, Philipp le Coutre, Hagop M. Kantarjian, Yaping Shou, Andreas Hochhaus, Kapil N. Bhalla, Md Ariful Haque, Norbert Gattermann, Giuliana Alimena and Gert J. Ossenkoppele and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Aaron Weitzman

37 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome–positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance

2007 540 citations Hagop M. Kantarjian, Francis J. Giles et al. Blood profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Aaron Weitzman United States	15	687	570	421	329	259	38	1.2k
Chao Zhu China	14	1.8k 2.7×	1.5k 2.7×	1.0k 2.4×	306 0.9×	146 0.6×	50	2.2k
Guozhi Gao United States	14	365 0.5×	453 0.8×	221 0.5×	802 2.4×	288 1.1×	27	1.4k
Jacob B. Allred United States	20	709 1.0×	476 0.8×	143 0.3×	661 2.0×	135 0.5×	67	1.7k
Marek Hus Poland	17	461 0.7×	239 0.4×	97 0.2×	319 1.0×	86 0.3×	110	869
Paola Aimone Switzerland	17	235 0.3×	229 0.4×	84 0.2×	549 1.7×	338 1.3×	43	1.1k
Joanne Lager United States	17	296 0.4×	389 0.7×	87 0.2×	439 1.3×	389 1.5×	37	1.2k
Juan Luis Steegmann Spain	20	1.9k 2.8×	1.6k 2.7×	929 2.2×	329 1.0×	121 0.5×	73	2.3k
Michael Boxer United States	16	394 0.6×	433 0.8×	164 0.4×	84 0.3×	148 0.6×	43	1.3k
Kevin Yee United States	9	499 0.7×	267 0.5×	43 0.1×	303 0.9×	362 1.4×	12	1.2k
Steven Knapper United Kingdom	23	1.7k 2.5×	825 1.4×	235 0.6×	286 0.9×	69 0.3×	91	2.4k

Countries citing papers authored by Aaron Weitzman

Since Specialization

Citations

This map shows the geographic impact of Aaron Weitzman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aaron Weitzman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aaron Weitzman more than expected).

Fields of papers citing papers by Aaron Weitzman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Aaron Weitzman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aaron Weitzman. The network helps show where Aaron Weitzman may publish in the future.

Co-authorship network of co-authors of Aaron Weitzman

This figure shows the co-authorship network connecting the top 25 collaborators of Aaron Weitzman. A scholar is included among the top collaborators of Aaron Weitzman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Aaron Weitzman. Aaron Weitzman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Call, Justin, et al.. (2024). Initial results from a first-in-human phase 1 study of SNS-101 (pH-selective anti-VISTA antibody) alone or in combination with cemiplimab in patients with advanced solid tumors.. Journal of Clinical Oncology. 42(16_suppl). 2600–2600. 5 indexed citations

Shimizu, Toshio, Kan Yonemori, Yasutoshi Kuboki, et al.. (2023). MO38-1 Phase 1 study of ABBV-155 ± paclitaxel in relapsed/refractory solid tumors: Results in Japanese patients. Annals of Oncology. 34. S1420–S1420. 1 indexed citations

Bendell, Johanna C., Lawrence Fong, Mark N. Stein, et al.. (2020). First-in-human phase I study of HPN424, a tri-specific half-life extended PSMA-targeting T-cell engager in patients with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 38(15_suppl). 5552–5552. 12 indexed citations

Hamilton, Erika, Patricia LoRusso, X. Cynthia, et al.. (2020). Abstract P5-11-01 : Phase 1 dose escalation study of a novel selective androgen receptor modulator (SARM), RAD140, in estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-), metastatic breast cancer. Cancer Research. 80(4_Supplement). P5–11. 1 indexed citations

Hamilton, E.P., Neelima Vidula, P. LoRusso, et al.. (2019). Abstract OT1-02-02: A phase 1, first-in-human, multi-part study of RAD140, an oral nonsteroidal selective androgen receptor modulator, in postmenopausal women with hormone receptor positive breast cancer. Cancer Research. 79(4_Supplement). OT1–2. 1 indexed citations

Daud, Adil, Harriet M. Kluger, Razelle Kurzrock, et al.. (2017). Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma. British Journal of Cancer. 116(4). 432–440. 52 indexed citations

Basch, Ethan, Karen A. Autio, Matthew R. Smith, et al.. (2014). Effects of Cabozantinib on Pain and Narcotic Use in Patients with Castration-resistant Prostate Cancer: Results from a Phase 2 Nonrandomized Expansion Cohort. European Urology. 67(2). 310–318. 31 indexed citations

Bennett, Antonia V., Sonya Eremenco, Christian Scheffold, et al.. (2013). Mode Equivalence of Interactive Voice Response (IVR) and Paper Versions of the Brief Pain Inventory (BPI) “Worst Pain” Item in Metastatic Castrate Resistant Prostate Cancer (mCRPC) Evaluated Conceptually Using Qualitative Methods. Value in Health. 16(7). A601–A601. 1 indexed citations

Daud, Adil, Harriet M. Kluger, Gerald M. Edelman, et al.. (2013). Activity of cabozantinib in metastatic uveal melanoma: Updated results from a phase II randomized discontinuation trial (RDT).. Journal of Clinical Oncology. 31(15_suppl). 9094–9094. 12 indexed citations

10.

Scher, Howard I., Matthew R. Smith, Christopher Sweeney, et al.. (2013). An exploratory analysis of bone scan lesion area (BSLA), circulating tumor cell (CTC) change, pain reduction, and overall survival (OS) in patients (pts) with castration-resistant prostate cancer (CRPC) treated with cabozantinib (cabo): Updated results of a phase II nonrandomized expansion (NRE) cohort.. Journal of Clinical Oncology. 31(15_suppl). 5026–5026. 10 indexed citations

11.

Singer, Jonathan B., Yaping Shou, Francis J. Giles, et al.. (2007). UGT1A1 promoter polymorphism increases risk of nilotinib-induced hyperbilirubinemia. Leukemia. 21(11). 2311–2315. 91 indexed citations

12.

Baetz, Tara, Elizabeth A. Eisenhauer, Lillian L. Siu, et al.. (2006). A phase I study of oral LY293111 given daily in combination with irinotecan in patients with solid tumours. Investigational New Drugs. 25(3). 217–225. 25 indexed citations

13.

Ottmann, Oliver G., Hagop M. Kantarjian, Richard A. Larson, et al.. (2006). A Phase II Study of Nilotinib, a Novel Tyrosine Kinase Inhibitor Administered to Imatinib Resistant or Intolerant Patients with Chronic Myelogenous Leukemia (CML) in Blast Crisis (BC) or Relapsed/Refractory Ph+ Acute Lymphoblastic Leukemia (ALL).. Blood. 108(11). 1862–1862. 17 indexed citations

14.

Giles, Francis J., Philipp le Coutre, Kapil N. Bhalla, et al.. (2006). A Phase II Study of Nilotinib, a Novel Tyrosine Kinase Inhibitor Administered to Patients with Imatinib Resistant or Intolerant Chronic Myelogenous Leukemia (CML) in Chronic Phase (CP), Accelerated Phase (AP) or Blast Crisis (BC) Who Have Also Failed Dasatinib Therapy.. Blood. 108(11). 2170–2170. 18 indexed citations

15.

Kantarjian, Hagop M., Norbert Gattermann, Andreas Hochhaus, et al.. (2006). A Phase II Study of Nilotinib A Novel Tyrosine Kinase Inhibitor Administered to Imatinib-Resistant or Intolerant Patients with Chronic Myelogenous Leukemia (CML) in Accelerated Phase (AP).. Blood. 108(11). 2169–2169. 18 indexed citations

16.

Richards, Donald, Helmut Oettle, Walter L. Vervenne, et al.. (2005). Randomized double-blind phase II trial comparing gemcitabine (GEM) plus LY293111 vs. GEM plus placebo in advanced adenocarcinoma of the pancreas. Journal of Clinical Oncology. 23(16_suppl). 4092–4092. 6 indexed citations

17.

Tiersten, Amy, Jennifer Y. Wo, Caron A. Jacobson, et al.. (2004). Cardiac toxicity observed in association with high-dose cyclophosphamide-based chemotherapy for metastatic breast cancer. The Breast. 13(4). 341–346. 18 indexed citations

18.

Adunsky, Abraham, Aaron Weitzman, Y. Fleissig, et al.. (2000). The relation of plasma total homocysteine levels to prevalent cardiovascular disease in older patients with ischemic stroke. Aging Clinical and Experimental Research. 12(1). 48–52. 13 indexed citations

19.

Weitzman, Aaron, Gary Shelton, Nancy Zuech, et al.. (2000). DEXAMETHASONE DOES NOT SIGNIFICANTLY CONTRIBUTE TO THE RESPONSE RATE OF DOCETAXEL AND ESTRAMUSTINE IN ANDROGEN INDEPENDENT PROSTATE CANCER. The Journal of Urology. 163(3). 834–837. 50 indexed citations

20.

Petrylak, Daniel P., Robert B. MacArthur, Jacqueline M. O’Connor, et al.. (1999). Phase I/II studies of docetaxel (Taxotere) combined with estramustine in men with hormone-refractory prostate cancer.. PubMed. 26(5 Suppl 17). 28–33. 74 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact